- Low-dose inhaled methoxyflurane offers greater and faster short-term pain relief than IV morphine in patients with severe trauma, with similar rates of adverse events (AEs).
Why this matters
- Methoxyflurane offers emergency clinicians a nonopioid option for trauma-related pain.
- A phase 3b, randomized, active-controlled, parallel-group, open-label study of 93 patients with moderate to severe trauma pain who were categorized into either a methoxyflurane (n=49) or standard analgesic treatment (SAT; IV morphine) group (n=44).
- Funding: Mundipharma Pharmaceuticals srl.
- Patients treated with methoxyflurane vs those treated with SAT showed:
- Higher reduction in visual analogue scale (VAS; 0-10) pain intensity in the first 10 minutes (adjusted mean treatment difference, −5.54 mm; P=.029).
- Higher proportion of VAS responders rate at 5 minutes (P=.021).
- Shorter median time to onset of pain relief (9 vs 15 minutes).
- Similar rates of nonserious adverse events (20.4% vs 4.8%).
- Study was not powered to determine noninferiority of methoxyflurane vs SAT.
Coauthored with Vijay Rathod, PhD.